(19)
(11) EP 2 875 029 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.12.2021 Bulletin 2021/50

(45) Mention of the grant of the patent:
10.11.2021 Bulletin 2021/45

(21) Application number: 13820038.1

(22) Date of filing: 18.07.2013
(51) International Patent Classification (IPC): 
C07D 513/04(2006.01)
C07D 487/04(2006.01)
C07D 413/12(2006.01)
A61K 31/4188(2006.01)
A61K 31/5377(2006.01)
A61P 31/06(2006.01)
 C07D 498/04(2006.01)
C07D 407/12(2006.01)
A61K 31/429(2006.01)
A61K 31/4427(2006.01)
A61P 31/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0014; A61K 9/0019; A61K 9/2059; A61K 9/2866; A61P 31/04; A61P 31/06; C07D 513/04
(86) International application number:
PCT/US2013/051125
(87) International publication number:
WO 2014/015167 (23.01.2014 Gazette 2014/04)

(54)

5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS

5,5-HETEROAROMATISCHE INFEKTIONSHEMMENDE VERBINDUNGEN

COMPOSÉS ANTI-INFECTIEUX 5,5-HÉTÉROAROMATIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.07.2012 US 201261672968 P

(43) Date of publication of application:
27.05.2015 Bulletin 2015/22

(73) Proprietor: University of Notre Dame du Lac
South Bend, IN 46617 (US)

(72) Inventors:
  • MORASKI, Garrett
    Bozeman Montana 59715 (US)
  • MILLER, Marvin J.
    South Bend Indiana 46635 (US)

(74) Representative: FRKelly 
27 Clyde Road
Dublin D04 F838
Dublin D04 F838 (IE)


(56) References cited: : 
WO-A1-95/29922
WO-A1-2011/073316
WO-A2-2008/038251
WO-A2-2008/087611
 WO-A1-2009/147431
WO-A2-2008/020405
WO-A2-2008/081399
WO-A2-2009/016560
   
  • ODELL L R ET AL: "Functionalized 3-amino-imidazo[1,2-a]pyridines: A novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 19, no. 16, 15 August 2009 (2009-08-15), pages 4790-4793, XP026419080, ISSN: 0960-894X [retrieved on 2009-06-14]
  • TERZIOGLU, NALAN ET AL.: 'Synthesis and anticancer evaluation of some new hydrazone derivatives of 2,6-dimethylimidazo[2,1-b][1,3,4]thiadiazol e-5- carbohydrazide.' EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY vol. 38, 2003, pages 781 - 786, XP004448330 & ABIGNENTE E. ET AL.: 'Research on heterocyclic compounds. XVIII. Imidazo[2,1-b]- 1,3,4-thiadiazole derivatives.' IL FARMACO, EDIZIONE SCIENTIFICA vol. 40, no. 3, 1984, pages 190 - 199, XP055182683
  • SYOICHI, BAN ET AL.: 'Studies on chemotherapeutics. XXXIX. Synthesis of imidazo compounds. IV. Imidazo[2,1-b]thiadiazole derivatives.' YAKUGAKU ZASSHI vol. 74, no. 2, 1954, pages 658 - 661, XP055182683
  • Victoria J. Compton ET AL: "Reaction of 2-aminothiazoles with reagents containing a C-halogen and a CO electrophilic centre", Journal of the Chemical Society, Perkin Transactions 1, no. 15, 1 January 1992 (1992-01-01), pages 2029-2032, XP055350996, GB ISSN: 0300-922X, DOI: 10.1039/P19920002029
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).